In MSD's oncology drug development, how do we prioritize extending overall survival versus improving quality of life for patients?

Introduction

In MSD's oncology drug development, we face a critical trade-off between extending overall survival and improving quality of life for patients. This decision impacts not only our product strategy but also the lives of countless individuals battling cancer. I'll analyze this trade-off through multiple lenses, considering patient outcomes, business implications, and ethical considerations.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking about the current landscape of oncology treatments. Could you provide more information on the specific types of cancer we're targeting and the current standard of care?

Why it matters: Helps tailor our approach to specific patient needs and market gaps. Expected answer: Focus on aggressive cancers with limited treatment options. Impact on approach: Would influence the balance between survival and quality of life priorities.

• Business Context: Based on MSD's portfolio, I assume this decision impacts multiple drug candidates. How does this trade-off align with our overall oncology strategy and revenue projections?

Why it matters: Ensures alignment with company goals and financial considerations. Expected answer: Balanced approach needed to maintain market leadership and profitability. Impact on approach: Would inform resource allocation and development priorities.

• User Impact: Considering patient demographics, are we primarily dealing with late-stage cancer patients or those in earlier stages of the disease?

Why it matters: Different patient groups may prioritize survival vs. quality of life differently. Expected answer: Mix of patient groups across various cancer stages. Impact on approach: Would influence how we weight survival vs. quality of life improvements.

• Technical: What's our current capability in developing drugs that can potentially address both survival and quality of life simultaneously?

Why it matters: Determines the feasibility of a balanced approach. Expected answer: Some promising candidates, but challenges in achieving both goals equally. Impact on approach: Would guide investment in specific research areas or potential partnerships.

• Resource: How does our current R&D budget and team capacity align with pursuing both survival and quality of life improvements?

Why it matters: Helps determine if we need to choose one focus or can pursue both. Expected answer: Limited resources require strategic allocation. Impact on approach: Would influence whether we need to prioritize one aspect or find creative ways to address both.